Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38a and BRD4. (2019)

First Author: Myers SM
Attributed to:  Discovery of ERK5 inhibitors for biomarker-driven clinical evaluation in cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.ejmech.2019.05.057

PubMed Identifier: 31212132

Publication URI: http://europepmc.org/abstract/MED/31212132

Type: Journal Article/Review

Volume: 178

Parent Publication: European journal of medicinal chemistry

ISSN: 0223-5234